Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 11/20 | 0.64 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 6/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL946938 | 0.86 | ADORA1 (0.63) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL946969 | 0.86 | ADORA1 (0.65) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL946703 | 0.84 | ADORA1 (0.65) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL3743139 | 0.84 | ADORA1 (0.67) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL946836 | 0.83 | ADORA1 (0.59) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL949863 | 0.83 | ADORA1 (0.65) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL5503144 | 0.82 | ADORA1 (0.64) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL948378 | 0.82 | ADORA1 (0.64) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL3741373 | 0.81 | ADORA1 (0.64) | ADORA1ADORA2AADORA3ADORA2BPDE4B | |
| SCHEMBL12359397 | 0.81 | ADORA1 (0.68) | ADORA1ADORA2AADORA3ADORA2BPDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989446-B2 | 4-amino 5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-08-02 | — | — | US | disclosed |
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. | 2011-01-13 | — | — | US | disclosed |
| US-7834002-B2 | 4-amino-5-cyanopyrimidine derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-07-31 | — | — | US | disclosed |
| EP-1740574-B1 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMA CO LTD (JP) | 2007-06-27 | — | — | EP | disclosed |
| EP-1740574-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | Otsuka Pharmaceutical Company, Limited (JP) | 2007-01-10 | — | — | EP | disclosed |
| WO-2005105778-A2 | 4-AMINO-5-CYANOPYRIMIDINE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009620-A1 | 4-Amino-5-cyanopyrimidine derivatives | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ADORA3 3/4885 |
| US-20080182854-A1 | 4-Amino-5-Cyanopyrimidine Derivatives | ADORA2A, ADORA1, ADORA3 | ADORA1 2/4885ADORA2A 1/4885ADORA3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.